Hormonal
Novel glucose-lowering agents, specifically GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide), induce significant weight loss and glycemic improvement, with tirzepatide showing remission rates of 66-81% in clinical trials.
Newer injectable medications like Tirzepatide and Semaglutide are highly effective for diabetes remission, with remission rates up to 81% for Tirzepatide. They work by mimicking gut hormones to improve insulin function and promote weight loss. Discuss these options with your doctor if lifestyle changes alone are insufficient.
Tirzepatide resulted in impressive remission rates ranging from 66% to 81% after 52 weeks dependent on the drug dosage... Semaglutide... studies showed an average weight reduction of 10 kg together with an average HbA1c of 6.4%
Why this rating
Based on Phase 3 trials and meta-analyses cited.
Source
Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
Dimitra Vasdeki et al. · Nutrients · 2022
DOI 10.3390/nu14224801
More from this paper
- Bariatric surgery, particularly Roux-en-Y gastric bypass and biliopancreatic diversion, induces Type 2 Diabetes remission in a majority of patients through mechanisms exceeding simple caloric restriction, including hormonal changes (GLP-1, PYY) and altered gut microbiome.Good
- Significant weight loss (typically >15 kg or >15% of baseline weight) induced by dietary interventions (Very Low-Calorie Diets or Low-Carbohydrate Diets) is the strongest predictor of Type 2 Diabetes remission, regardless of the specific macronutrient composition.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →